AIDS vaccine
trial shows positive results

Atlanta-based GeoVax Labs today reported positive safety and efficacy results for two ongoing AIDS vaccine trials. The GeoVax vaccines being tested are designed to prevent the development of AIDS caused by HIV-1 by vaccinating individuals prior to infection.

Results show that one tenth of a full dose is safe and stimulates a potentially protective anti-HIV-1 immune response, indicated by the presence of antibodies and T cells that recognize and control viral infections.

Based on the safety demonstrated in this trial, a full-dose human trial of 36 volunteers started in September. The full dose of AIDS vaccine approximates the dose size that protected 22 of 23 (96%) nonhuman primates for more than three years against development of AIDS. (The Advocate)